CSB 2.009 Note
48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2018 No. 752, eff. 8-13-18; correction made under s.
35.17, Stats.,
Register August 2018 No. 752;
CR 19-010: cr.
Register June 2020 No. 774, eff. 7-1-20; correction made under s.
35.17, Stats.,
Register June 2021 No. 786.
CSB 2.009 Note
CSB 2.64 Addition of N-Ethylpentylone to schedule I. Section
961.14 (7) (L) 34., Stats., is created to read:
CSB 2.009 Note
961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2018 No. 754, eff. 10-8-18;
CR 19-011: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.009 Note
CSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section
961.22 (7), Stats., is created to read:
CSB 2.009 Note
961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register October 2018 No. 754, eff. 10-15-18;
CR 19-012: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.009 Note
CSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section
961.14 (4) (tb),
49.,
50.,
51.,
52., and
53., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
CSB 2.009 Note
50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
CSB 2.009 Note
51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
CSB 2.009 Note
52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
CSB 2.009 Note
53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2019 No. 759, eff. 3-11-19;
CR 20-048: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section
961.20 (2) (ap) and
(2m) (g), Stats., are created to read:
CSB 2.009 Note
961.20 (2) (ap) Brexanolone;
CSB 2.009 Note
(2m) (g) Solriamfetol.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2019 No. 763, eff. 7-22-19;
CR 20-049: cr.
Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s.
35.17, Stats.,
Register June 2021 No. 785.
CSB 2.009 Note
CSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section
961.14 (7) (L) 35. to
40., Stats., is created to read:
CSB 2.009 Note
961.14 (7) (L) 35. N-Ethylhexedrone.
CSB 2.009 Note
36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
CSB 2.009 Note
37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
CSB 2.009 Note
38. 4'-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
CSB 2.009 Note
39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
CSB 2.009 Note
40. 4'-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register August 2019 No. 764, eff. 8-19-19;
CR 20-050: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.69 Addition of Noroxymorphone to schedule II. Section
961.16 (2) (a) 10m., Stats., is created to read:
CSB 2.009 Note
961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2019 No. 767, eff. 11-11-19;
CR 20-051: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section
961.14 (4) (tb) 38m. and
43m., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
CSB 2.009 Note
43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
CSB 2.009 History
History:
EmR2017: emerg. cr., eff. 6-26-20;
CR 20-022: cr.
Register May 2021 No. 785, eff. 6-1-21.
CSB 2.009 Note
CSB 2.71 Addition of lasmiditan to schedule V. Section
961.22 (8), Stats., is created to read:
CSB 2.009 Note
961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2020 No.771, eff. 3-23-20;
CR 20-058: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section
961.14 (2) (pe) and
(4) (jm), Stats., are created to read:
CSB 2.009 Note
961.14 (2) (pe) Isotonitazene;
CSB 2.009 Note
961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
CSB 2.009 History
History:
EmR2013: emerg. cr., eff. 6-5-20;
CR 20-023: cr.
Register May 2021 No. 785, eff. 6-1-21; correction made under s.
35.17, Stats.,
Register May 2021 No. 785.
CSB 2.009 Note
CSB 2.73 Addition of cenobamate to schedule V. Section
961.22 (9), Stats., is created to read:
CSB 2.009 Note
961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2020 No. 773, eff. 5-18-20;
CR 20-075: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.74 Addition of Lemborexant to schedule IV. Section
961.20 (2) (eqm), Stats., is created to read:
CSB 2.009 Note
961.20 (2) (eqm) Lemborexant.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2020 No.771, eff. 5-18-20;
CR 20-076: cr.
Register July 2021 No. 787, eff. 8-1-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787.
CSB 2.009 Note
CSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section
961.14 (4) (t) 4., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.009 Note
(2) Section 961.22 (7) is repealed.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register June 2020 No. 774, eff. 6-29-20;
CR 20-077: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:
CSB 2.009 Note
961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
CSB 2.009 Note
1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
CSB 2.009 Note
2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2020 No. 774, eff. 6-29-20;
CR 20-078: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.77 Scheduling of flualprazolam. Section
961.20 (2) (ef), Stats., is created to read:
CSB 2.009 Note
961.20 (2) (ef) Flualprazolam;
CSB 2.009 History
History:
EmR1037: emerg. cr., eff. 10-27-20;
CR 20-078: cr.
Register July 2021 No. 787, eff. 8-1-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787.
CSB 2.009 Note
CSB 2.78 Addition of crotonyl fentanyl to schedule I. Section
961.14 (2) (nd) 9m., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2020 No. 779, eff. 11-23-20;
CR 22-011: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.009 Note
CSB 2.79 Addition of remimazolam to schedule IV. Section
961.20 (2) (mo), Stats., is created to read:
CSB 2.009 Note
961.20 (2) (mo) Remimazolam;
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2020 No. 779, eff. 11-23-20;
CR 22-014: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.009 Note
CSB 2.80 Scheduling of oliceridine. Section
961.16 (3) (ta), Stats., is created to read:
CSB 2.009 Note
961.16 (3) (ta) Oliceridine;
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2020 No. 780, eff. 12-14-20;
CR 21-098: cr.
Register August 2022 No. 800, eff. 9-1-22.
CSB 2.009 Note
CSB 2.81 Addition of brorphine to schedule I. Section
961.14 (2) (et), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (et) Brorphine;
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2021 No. 785, eff. 4-26-21; correction made under s.
35.17, Stats.,
Register May 2021 No. 785;
CR 22-016: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.009 Note
CSB 2.82 Addition of Serdexmethylphenidate to schedule IV. Section
961.20 (2m) (em), Stats., is created to read:
CSB 2.009 Note
961.20 (2m) (em) Serdexmethylphenidate.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-12-21;
CR 22-032: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.009 Note
CSB 2.83 Addition of ten (10) fentanyl-related substances to schedule I. Section
961.14 (2) (nd) 21.,
22.,
23.,
24.,
25.,
26.,
27.,
28.,
29., and
30., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 21. N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2'-fluoro ortho-fluorofentanyl; 2'-fluoro 2-fluorofentanyl);
CSB 2.009 Note
22. N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4'-methyl acetyl fentanyl);
CSB 2.009 Note
23. N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (b'-phenyl fentanyl; beta'-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);
CSB 2.009 Note
24. N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (
b-methyl fentanyl);
CSB 2.009 Note
25. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);
CSB 2.009 Note
26. N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);
CSB 2.009 Note
27. 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);
CSB 2.009 Note
28. N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4-methylfentanyl);
CSB 2.009 Note
29. N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);
CSB 2.009 Note
30. N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl).
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-033: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.009 Note
CSB 2.84 Addition of alfaxalone to schedule IV. (1) Section 961.20 (2) (a), Stat., is repealed and recreated to read:
CSB 2.009 Note
961.20 (2) (a) Alfaxalone;
